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MicroRNAs species are short, noncoding RNAs formed of
19e24 nucleotides (nt).1 MicroRNA was first isolated in
Caenorhabditis elegans in the early 1990s.2 Initially, only
intracellular microRNA species were identified; however,
with the advancement of research in this area, many
microRNA families were isolated in different body fluids. So
far, about 700 species of microRNA were identified in Homo
sapiens.2 The characteristic features of these species are
their high stability and specificity and selectivity. Recent
studies have demonstrated that the diversity in the bio-
logical pathways through which microRNAs are formation
can serve as an important feature for utilizing them as
markers for prognosis of disease.3 In addition, their pres-
ence in significant concentrations in plasma or other body
fluids makes them ideal as biomarkers in clinical practice.
In this paper, the authors present different ways of using
microRNA as a specific biomarker for the multiple trauma
patients.
Biochemical characteristics of microRNAs
From the biochemical point of view, microRNAs are short
RNA species composed of 19e24 nt. The biogenesis of
microRNAs begins in the nucleus with the transcription of
protein-encoding genes by RNA polymerase II, which pro-
duces a primary form of microRNA (pri-microRNA).4pri-miRNA miRNA gene 
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HDL Z high-density lipoprotein; TRBP Z trans-activator RNA bindThrough the polyadenylation of pri-microRNA, the precur-
sor for the synthesis of mature microRNAs (pre-microRNA) is
obtained. For this reaction to occur, RNA polymerase III
(Drosha) and the DiGeorge critical region 8 complex are
required.5 Once the pre-microRNA is synthesized, it is
transported to the cytoplasm by the nucleocytoplasmic
transporter (Exportin-5).6 Once inside the cytoplasm,
through the action of Dicer complex, the pre-microRNA
forms double-stranded mature microRNA (19e24 nt) and
microRNA* (passenger strand), which is subsequently
degraded by argonaute. The synthesized microRNA is
captured by the RNA-induced silencing complex.6,7 The
microRNAs reach the systemic circulation through the pas-
sage across the cell membrane by two specific mechanisms,
namely, passive release and active release. In the case of
passive release, microRNAs are released into the plasma
during cell death in the form of apoptotic bodies. Active
release refers to the release of microRNAs into the plasma
in the form of microvesicles, exosomes, and high-density
lipoproteins particles (Figure 1).8,9Bioanalytical aspects
In the human body, circulating microRNAs can be identified
in a number of fluids such as venous blood, serum, plasma,
saliva, urine, cerebrospinal fluid, seminal fluid, pleural
fluid, peritoneal fluid, amniotic fluid, tears, and bronchial
lavage (Table 1).10,11 Weber et al10 have identified thepre-miRNA Exportin 5 pre-miRNA 
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Table 1 Specificity of microRNAs in biological fluids of the human organism.
Body fluid microRNAs References
Plasma microRNA-224, microRNA-483-3p, microRNA-518f, microRNA-508-3p, microRNA-551b,
microRNA-182, microRNA-135a, microRNA-139-3p, microRNA-801, microRNA-369-3p,
microRNA-519d, microRNA-299-5p, microRNA-373, and microRNA-330-5p
10,15,16
Venous blood microRNA-16, microRNA-20a, microRNA-106a, microRNA-126, microRNA-150, microRNA-185,
microRNA-451, and microRNA-451a
13
Tears microRNA-637 4
Saliva microRNA-182, microRNA-450b-5p, microRNA-622, microRNA-141, microRNA-26a, microRNA-
145, microRNA-135b, microRNA-281, microRNA-96, microRNA-1228, and microRNA-431
10,15
Semen microRNA-508-5p, microRNA-644, microRNA-17, microRNA-380, microRNA-29b-2, and
microRNA-240
13
Amniotic fluid microRNA-636, 92a-1, microRNA-26b, microRNA-376b, microRNA-556-5p, and microRNA-593 13,15
Peritoneal fluid microRNA-129, microRNA-583, microRNA-223, microRNA-627, and microRNA-29b-1 15
Colostrum microRNA-18a, microRNA-513a-50, microRNA-10b, microRNA-192, microRNA-193b, and
microRNA-130a
10
Menstrual blood microRNA-185, microRNA-144, microRNA-412, and microRNA-451 10,13
Vaginal secretion microRNA-617 and microRNA-891a 10,16,17
Breast milk microRNA-10a, microRNA-28-5p, microRNA-150, microRNA-193b, microRNA-217, microRNA-
518c, and microRNA-92b
15
Cerebrospinal
fluid
microRNA-577 15
MicroRNAs as biomarkers for polytrauma 133concentration of microRNAs in 12 biological fluids.10 Based
on their study results, the existence of a large number of
microRNAs in these fluids was reported: 359 microRNA
species in amniotic fluid, 429 in breast milk, 260 in bron-
chial lavage, 212 in cerebrospinal fluid, 386 in colostrum,
397 in peritoneal fluid, 359 in plasma, 458 in saliva, 436 in
seminal fluid, 320 in tears, and 204 in urine.11,12 Zubakov
et al13 evaluated the expression of microRNAs in five types
of biological fluids by microarray and reverse transcription-
polymerase chain reaction data analyses, and reported the
existence of a series of microRNAs, including the following:
microRNA-185, microRNA-144 (menstrual blood),
microRNA-20a, microRNA-106a, microRNA-185 (venous
blood), microRNA-943, microRNA-135a, microRNA-10a,
microRNA-507 (semen), microRNA-583, microRNA-518c,Table 2 Specific microRNA species for the oncologic diagnosis.
Oncological pathology microRNAs
Breast cancer microRNA-10b, microRNA-341, and m
Prostate cancer microRNA-16, microRNA-92a, microR
microRNA-34b, microRNA-328, micro
microRNA-640, microRNA-766, and m
Ovarian cancer microRNA-21, microRNA-92, microRN
Lung cancer microRNA-7i, microRNA-146b, microR
microRNA-15b, microRNA-19b, micro
microRNA-320, microRNA-375, micro
Colorectal cancer microRNA-29a, microRNA-92a, micro
Bladder cancer microRNA-126 and microRNA-182
Esophageal cancer microRNA-1246, microRNA-31, and m
Nasopharyngeal cancer microRNA-17, microRNA-20a, microR
Renal cancer microRNA-1233
Head and neck carcinoma microRNA-425-5p and microRNA-93-5
Hepatocellular carcinoma microRNA-9-3p, microRNA-9, microRN
microRNA-18a, microRNA-21, microRmicroRNA-208b (saliva), microRNA-617, and microRNA-891a
(vaginal secretion). To be used as biomarkers, microRNA
species must fulfill a number of features, among which the
most important are low cost, simple techniques for isola-
tion and analysis, noninvasive techniques, and high speci-
ficity and selectivity. Analytical methods for identifying
microRNAs present in these fluids are hybridization
(microarray), quantitative reverse transcription-
polymerase chain reaction, and RNA sequencing.13,14Circulating microRNAs in cancer
A series of studies suggested the possible link between the
expression of microRNAs and different forms of cancer. TheReferences
icroRNA-195 15,22,23
NA-103, microRNA-107, microRNA-197,
RNA-485-3p, microRNA-92b, microRNA-636,
icroRNA-885-5p
15,20,24,25
A-93, microRNA-126, and microRNA-92a 15,26
NA-206, microRNA-21, microRNA-10b,
RNA-182, microRNA-197, microRNA-222,
RNA-574-5p, microRNA-660, and microRNA-1254
15,18,19
RNA-378, microRNA-21, and microRNA-18a 27,28
28,29
icroRNA-1322 28,30,31
NA-29c, and microRNA-223 1
20
p 21
A-10a, microRNA-10b, microRNA-15a,
NA-27a, microRNA-92, and microRNA-96
11,15,28
134 O.H. Bedreag et al.most commonly studied types of cancers in these studies
are prostate cancer, renal cancer, breast cancer, ovarian
cancer, lung cancer, bladder cancer, hepatocellular carci-
noma, gastrointestinal cancer, and head and neck can-
cer.15e17 Billeter et al18 reported an increased plasmatic
concentration of the following series of microRNAs in lung
cancer: microRNA-10b, microRNA-15b, microRNA-17,
microRNA-19b, microRNA-182, microRNA-182, microRNA-
197, microRNA-222, microRNA-320, microRNA-375,
microRNA-574-5p, microRNA-660, and microRNA-1254. In
hepatocellular carcinoma cases, Borel et al11 identified the
following series of microRNAs whose plasmatic concentra-
tions are significantly elevated: microRNA-9-3p, microRNA-
9, microRNA-10a, microRNA-10b, microRNA-15a, microRNA-
18a, microRNA-21, microRNA-27a, microRNA-93, and
microRNA-96.11 Wang et al19 studied the expression of
microRNAs in gastrointestinal tumors and reported the
increased plasmatic levels for microRNA-601, microRNA-
760, microRNA-29a, microRNA-92a. In colorectal cancer
cases, microRNA-378, microRNA-21, microRNA-18a have
been identified; in esophageal cancer, microRNA-1246,
microRNA-31, and microRNA-1322 were identified.20 In
renal cancer, Wulfken and collaborators20 highlighted the
presence of microRNA-1233. Summerer et al21 reported
high levels of microRNA-425-5p and microRNA93-5p in head
and neck cancer cases. Table 2 presents the microRNA
species specific for the oncological pathologies. Based on
circulating microRNAs, many previously published studies
have highlighted the characteristic features for diagnosis of
cancer using noninvasive diagnostic methods. A number of
factors support the use of microRNAs as biomarkers for
diagnosis including high stability, specificity, and
selectivity.22e29microRNAs as biomarkers for critically ill
polytrauma patients
Patients with multiple trauma in the intensive care unit
(ICU) present a significant challenge for doctors because of
complexity of their conditions (multiple physiological,
biochemical, and systemic imbalances as well as the mul-
tiple organ damage). The most specific injuries suffered by
polytrauma patients that cause a significant decrease in
survival rates are brain injuries, spinal cord injuries, severe
pulmonary injuries, severe abdominal injuries, and severe
burns. In a high percentage trauma patients, severe hem-
orrhagic shock associated with vascular and cardiac failures
has been noted.30e34 Post-traumatic secondary complica-
tions commonly noted in critically ill trauma patients are
microvascular disease, systemic inflammations, sepsis, and
multiple organ failure. Physiological, biochemical, and
metabolic imbalances are associated with primary injuries.
The secondary post-traumatic injuries significantly
contribute to the decrease of the survival rate in these
patients. Numerous studies have been conducted regarding
the identification of expression of microRNAs in the
different traumas that play a significant role in reducing the
survival rates of critically ill polytrauma patients.
Shortly after a traumatic event, these patients suffer
systemic inflammatory response syndrome (SIRS). However,
due to excessive production of proinflammatory molecules,activation of the coagulation cascade, hypermetabolism,
and physiological imbalances, SIRS progresses into
sepsis.35e39 The intensity of the trauma, post-traumatic
secondary lesions, and genetic characteristics determine
the evolution of SIRS. The following stages are noted after a
traumatic event: hyperinflammation (first phase), followed
by an equilibrium state, a mixed antagonist response syn-
drome, which characterized by a decrease in the concen-
tration of proinflammatory mediators and an increase in the
concentration of anti-inflammatory mediators. Following
this inflammatory stage is the compensatory anti-
inflammatory response syndrome (CARS), which is charac-
terized by an increase in the concentration of inflammatory
mediators. Depending on a number of pathophysiological
aspects, critically ill polytrauma patients may progress to
multiple organ dysfunction syndrome (MODS) from SIRS/
CARS (Figure 2). Endothelial dysfunctions are also largely
responsible for augmenting the inflammatory response. The
activation of nuclear factor transcription-kB (NF-kB) mod-
ulates the activation of specific adhesion molecules, such
as vascular cell adhesion molecules-1, intercellular adhe-
sion molecules-1, and E selectin. Moreover, the activity of
NF-kB is responsible for the modulation of some proin-
flammatory cytokines such as tumor necrosis factor-alpha
(TNF-a) and interleukin-1-beta (IL-1b). Sun et al40 studied
the role of microRNAs in the NF-kB pathway and reported
that microRNA-181b is responsible for modulating NF-kB
pathway in inflammation and sepsis. In addition, it was
suggested that in patients with sepsis admitted to ICUs, the
expression of microRNA-181b is greatly reduced. Statisti-
cally significant correlations between increased TNF-a and
IL-1 levels and an increased expression of miRNA-146 have
also been reported.41 Recent studies have shown that a
number of microRNAs species are involved in modulating
the activity of antigen-presenting cells or T cells. Among
these are 17e92 microRNA, microRNA-181, microRNA-146a,
microRNA-155, microRNA-511, microRNA-132, microRNA-
122, microRNA-21, microRNA-125b, microRNA-187, and
microRNA-223.42
Traumatic brain injury (TBI) is responsible for a high
percentage of death or disability in surviving patients.
Recently, many studies were also carried out on the diag-
nosis and prognosis of TBI. Assessing the stage of brain
trauma based on expression of microRNAs has also been
reported.33 Liu et al34 have analyzed the expression of
microRNAs in mitochondrial fractions of rat hippocampal
tissue and reported significant increases in the expressions
of microRNA-155 and microRNA-223 following TBI. The au-
thors of that study also reported increased plasmatic con-
centrations of microRNA-142-3p and microRNA-221 after
TBI in laboratory animals.34
Sharma et al35 reported changes in some microRNAs
species in laboratory animals with TBI. These species
include microRNA-199a-3p, microRNA-214-3p, microRNA-
218-5p, microRNA-196c, microRNA-31-5p, and microRNA-
106b. Liu et al36 carried out a study on the expression of
microRNAs in TBI and highlighted significant increases in the
expression of microRNA-144, microRNA-153, and microRNA-
340-5p. Another important cause of death in the ICU is
spinal cord injury (SCI).37 SCI induces a series of secondary
injuries caused by the various related physiopathologies
that have a direct impact on increased mortality. Godwin et
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MicroRNAs as biomarkers for polytrauma 135al38 studied the expression of microRNAs in laboratory an-
imals with SCI and reported a decrease in the plasma con-
centrations of microRNA-137, microRNA-181, microRNA-
219-2-3p, and microRNA-7, and an increase in the concen-
tration of microRNA-21.38 A common pathology in poly-
trauma patients is respiratory failure, which is caused by
either direct injuries (rib fractures, hemothorax, pneumo-
thorax, and pulmonary parenchymal injury) or indirect in-
juries associated with mechanical ventilation or sepsis.
Among them, acute respiratory distress syndrome (ARDS)
has the most significant impact on worsening clinical sta-
tus.39 ARDS is mainly characterized by pulmonary injuries
and severe inflammation of the lung parenchyma. Huang
et al37 conducted an analysis of microRNA expression in
laboratory animals with ARDS, and reported significant
changes in the expression of 27 microRNA species.37 They
reported significant increases in the plasma concentrations
of microRNA-344, microRNA-346, microRNA-99a, microRNA-
127, microRNA-128b, microRNA-135b, microRNA-30a, and
microRNA-30b, but decreases in the plasma concentrations
of microRNA-24, microRNA-26a, and microRNA-126.37 Kid-
ney damage is another significant concern while treating
critically ill patients. Godwin et al38 reported modifications
in the expression of a series of microRNA species after se-
vere renal dysfunction in laboratory animals. Their studies
showed a significant increase in the expression of
microRNA-21, especially in the case of renal ischemic
reperfusion injury. There are numerous studies on the use
of circulating microRNAs as biomarkers for the diagnosis of
trauma; however, at present, many studies are only con-
ducted on laboratory animals, as no concrete results are
available for human patients.Expression of microRNAs in sepsis
Sepsis is characterized by severe systemic inflammation
during generalized infection.41,42 In patients admitted to
the ICU, sepsis is a leading cause of death because of
multiple organ failure. For a polytrauma patient, SIRS is
initially triggered, followed by sepsis, severe sepsis, septic
shock, and eventually MODS.43 According to the American
College of Chest Physicians and the Society of Critical Care
Medicine, there are a number of criteria for defining the
aforementioned conditions: SIRS is defined by core body
temperature greater than 38C or less than 36C; heart rate
of 90 bpm or greater or more than 20 breaths per minute or
PaCO2 less than 32 mmHg; white blood cell levels of 12,000/
mL or greater or 4,000/mL or less, or more than 10% of
immature forms; sepsis is defined by at least two SIRS
criteria caused by known or suspected infection; severe
sepsis is defined by sepsis associated with organ dysfunction
or hypotension and hypoperfusion; septic shock is defined
by sepsis with persistent or refractory hypotension or tissue
hypoperfusion despite adequate fluid resuscitation; MODS is
defined by presence of organ dysfunction in an acutely ill
patient such that homeostasis cannot be maintained
without intervention.44 In recent years, research studies in
this field have focused on identifying specific biomarkers
that can be correlated with the stage and severity of sepsis.
The biomarkers used in this sense are C-reactive protein,45
procalcitonin,45 and IL-6.46 Recently, questions have arisen
about the use of microRNAs as biomarkers for the predic-
tion and monitoring of sepsis in critically ill patients. A
significant number of studies analyzed microRNA profiles in
patients with sepsis (Table 3).47 At present, a number of
Table 3 Expression of microRNAs species in patients with
sepsis.
References Expression
in sepsis
patients
References
microRNA-15a, microRNA-16 Up 47
microRNA-122, microRNA-146a,
microRNA-223, microRNA-483-5p,
microRNA-499-5p, microRNA-574-
5p, microRNA-150, and
microRNA-193b
Down 47
microRNA-182, microRNA-199a-5p,
microRNA-203, microRNA-211,
microRNA-222, and microRNA-29b
Up 49
microRNA-233 and microRNA-146 Down 50
microRNA-150 and microRNA-342-5p Down 46
microRNA-466I Down 45
136 O.H. Bedreag et al.microRNAs can be correlated with sepsis. Vasilescu et al48
conducted a study on microRNA species in patients with
sepsis, and reported a significant decrease in the circu-
lating microRNA-150 level. In their study, they correlated
the decrease in the plasma microRNA-150 level with
increased proinflammatory cytokines and IL-18.49 Wang
et al50 also reported similar significant decreases in the
levels of microRNA-223 and microRNA-146. Li et al45 re-
ported decreased plasma levels of microRNA-466I in pa-
tients with sepsis. The innate immune response represents
the first line of deference in the fight against invading
pathogens.51 Petrocca et al51 have analyzed the expression
of microRNAs in circulating leukocytes in an in vivo exper-
imental study of acute inflammation caused by Escherichia
coli.51 The results of their study demonstrated substantial
changes in the expression of microRNAs based on a number
of factors, including innate pathogen (microRNA-146b,
microRNA-150, and microRNA-143); apoptosis (microRNA-
150 and microRNA-143); and cytokines (microRNA-342 and
microRNA-143).52 Inflammatory mediators determine the
type of inflammatory response, acting at the systemic
level, that has a synergistic or antagonistic effect on other
structures and biochemical functions causing adverse ef-
fects, including severe tissue injury and death. Inflamma-
tory cascade is triggered by the presence of specific
microorganisms and toxins biosynthesized by them.47,49e51
As clearly explained in the literature, a number of bacte-
ria produce a single toxin responsible for triggering the
respective disease, whereas many others produce exotoxins
that are directly involved in toxic shock. Some bacteria
produce both exotoxins and endotoxins, whereas some only
produce endotoxins. The most frequently implicated toxin
in septic shock is endotoxin. This is present in the bacterial
wall, as it is a lipideproteineglucide macromolecular
complex.52 Endotoxemia is noted in critically ill patients
with septic shock, infected by Gram-negative microorgan-
isms, and multiple organ dysfunction. Specific immune
response acts in close cooperation with the nonspecific one
in phagocytosis and in the processing of infectious anti-
gens.53 Biochemichal-mediated immunity represents a goldgoal in the specific immune response in infections by killing
the bacteria, neutralizing of toxins and by increasing the
phagocytosis. In the current moment for the detection of
causative pathogens in sepsis diagnostics is used as an
extremely high preponderance the blood cultures.53 A
promising method in this regard is the use of specific
microRNAs for the detection of microbiological species.
Numerous studies have highlighted the role of microRNAs in
the pathogenesis of viruses and bacteria. The activity of
bacteria in the human body significantly alters the
expression of microRNAs, and these changes are consider-
ably noticeable. Moreover, the expression of microRNAs is
modified according to different immune responses in bac-
terial infections. A number of studies have demonstrated
an increase in the expression of microRNA-146 and
microRNA-155 in Helicobacter pylori, Listeria mono-
cytogenes, Mycobacterium tuberculosis, and Salmonella
enterica infections.53e58 Zheng et al56 studied the expres-
sion of microRNAs in the case of Brucella melitensis and
reported the presence of microRNA-92a, microRNA-93,
microRNA-181b, and microRNA-1981. In Pseudomonas aer-
uginosa infections, significant changes in the expression of
microRNA-302b and microRNA-233 were reported. Hsieh
et al59 studied the expressions of microRNAs species in
laboratory mice injected with lipoteichoic acid specific for
Gram-positive bacteria and those injected with lipopoly-
saccharide specific for Gram-negative bacteria. Their study
results showed significant increases in the levels of
microRNA-451, microRNA-668, microRNA-1902, and micro-
RNA-1904.59 Thus, their study results provided a new
perspective to differentiate between Gram-positive and
Gram-negative bacterial infections.
Conclusion
Because of their characteristics and functions, microRNAs
are being increasingly studied and used as a biomarker for a
number of diseases in the clinical field. MicroRNAs released
by a tissue during tissue aggression or a period of prolonged
stress (inflammation, infection, sepsis, or organ dysfunc-
tion) make them an ideal candidate for use as a diagnostic
biomarker in the bioanalytical procedures of diagnosis. In
addition, microRNAs can also be used to carry out specific
treatments to modulate at the molecular level a number of
specific physiological pathways for the critically ill pa-
tients. In conclusion, we can affirm that improving and
strengthening diagnostic methods based on identifying
microRNAs are impetuous required.
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